Zacks: Brokerages Anticipate BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to Post -$0.01 EPS

Wall Street brokerages expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to announce earnings of ($0.01) per share for the current quarter, Zacks reports. Five analysts have made estimates for BioDelivery Sciences International’s earnings. The highest EPS estimate is $0.01 and the lowest is ($0.03). BioDelivery Sciences International reported earnings of ($0.10) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 90%. The business is scheduled to report its next quarterly earnings report after the market closes on Tuesday, November 12th.

According to Zacks, analysts expect that BioDelivery Sciences International will report full year earnings of ($0.22) per share for the current year, with EPS estimates ranging from ($0.28) to ($0.15). For the next financial year, analysts forecast that the company will post earnings of $0.22 per share, with EPS estimates ranging from $0.09 to $0.46. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.12. BioDelivery Sciences International had a negative net margin of 34.73% and a negative return on equity of 0.85%. The firm had revenue of $29.68 million during the quarter, compared to analyst estimates of $25.30 million.

A number of equities analysts have recently weighed in on the stock. ValuEngine raised shares of BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 29th. BidaskClub cut shares of BioDelivery Sciences International from a “strong-buy” rating to a “buy” rating in a research report on Friday. Finally, William Blair reissued a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $6.20.

BDSI traded down $0.01 during trading on Friday, reaching $5.79. 632,800 shares of the company’s stock were exchanged, compared to its average volume of 894,412. The company’s fifty day moving average price is $5.08 and its 200-day moving average price is $4.56. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.09 and a current ratio of 2.34. BioDelivery Sciences International has a fifty-two week low of $2.80 and a fifty-two week high of $6.12. The firm has a market capitalization of $519.23 million, a PE ratio of -7.93 and a beta of 0.39.

In other news, Director Mark A. Sirgo sold 157,177 shares of BioDelivery Sciences International stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $4.79, for a total transaction of $752,877.83. Following the transaction, the director now directly owns 1,874,637 shares of the company’s stock, valued at $8,979,511.23. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $4.29, for a total transaction of $34,320.00. Following the completion of the sale, the director now directly owns 588,754 shares in the company, valued at $2,525,754.66. The disclosure for this sale can be found here. Over the last three months, insiders have sold 373,364 shares of company stock worth $1,859,559. Insiders own 8.94% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. BTR Capital Management Inc. bought a new stake in BioDelivery Sciences International in the 2nd quarter valued at $47,000. Cutter & CO Brokerage Inc. bought a new stake in BioDelivery Sciences International in the 2nd quarter valued at $60,000. Nisa Investment Advisors LLC bought a new stake in BioDelivery Sciences International in the 3rd quarter valued at $148,000. Resources Investment Advisors LLC. bought a new stake in BioDelivery Sciences International in the 2nd quarter valued at $172,000. Finally, Acadian Asset Management LLC lifted its position in BioDelivery Sciences International by 348.9% in the 2nd quarter. Acadian Asset Management LLC now owns 58,243 shares of the specialty pharmaceutical company’s stock valued at $271,000 after acquiring an additional 45,269 shares in the last quarter. 66.54% of the stock is currently owned by institutional investors and hedge funds.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

See Also: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.